All In Biotech

Drug Trial Radar · NCT07640217

A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a)

A Phase II Randomized, Double-Blind, Parallel-group, Placebo-Controlled Trial of SYH2068 Injection in Adults With Elevated Lipoprotein(a)

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Mar 30, 2028

Study completion Sep 30, 2028

Sponsor

Sponsor type
Industry
First posted
Jun 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of SYH2068 injection in patients with elevated lipoprotein(a).

Conditions

  • Adult Participants With Elevated Lipoprotein(a)

Interventions

  • SYH2068 Dose 1Drug

    Administered by subcutaneous injection.

  • SYH2068 Dose 2Drug

    Administered by subcutaneous injection.

  • SYH2068 Dose 3Drug

    Administered by subcutaneous injection.

  • PlaceboDrug

    Administered by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in Lp(a) from baseline to Day 60~180Time frame: Day 60~180

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.